This bill, titled the Hospitals As Naloxone Distribution Sites (HANDS) Act, aims to significantly expand access to opioid overdose reversal drugs by requiring no-cost coverage under major federal health programs. Specifically, it amends titles XVIII and XIX of the Social Security Act and title 10, United States Code, to ensure that Medicare, Medicaid, and TRICARE beneficiaries can receive these life-saving medications without cost-sharing. The core purpose is to facilitate the preventive distribution of these drugs to individuals identified as being at risk for an opioid overdose. The legislation defines a "preventive opioid overdose reversal drug" as an intranasal or intramuscular medication furnished by a qualified clinical professional to an inpatient or emergency department/ambulatory surgical center patient. This distribution must occur at the time of discharge or departure, provided the professional determines the individual is at risk of an opioid overdose and includes instructions for administration. These provisions are set to take effect on January 1, 2026 , ensuring a standardized approach to preventive care across these programs. Under Medicare, the bill adds these drugs to covered services and explicitly prohibits deductibles and cost-sharing for both traditional Medicare and Medicare Advantage plans. For Medicaid, it mandates state coverage of these drugs and similarly prohibits any cost-sharing, while also applying existing rebate requirements. TRICARE beneficiaries will also be exempt from cost-sharing for these preventive drugs. Additionally, the bill directs the FDA and HHS to issue guidance within one year to state boards and hospitals, respectively, on enhancing safe dispensing and billing practices, though it clarifies that providers are not mandated to furnish the drug.